OncoC4 presents data indicating immunotherapy has potential to become a ‘new class’ of Alzheimer’s drug...

Ein neues Medikament von Biontech könnte Patienten, die unter weit fortgeschrittenem Lungenkrebs leiden, etwas Hoffnung geben.

A Rockville clinical-stage biotech has closed a $50 million Series B round to advance its potential treatments for cancer and neurodegenerative diseases.

OncoC4 Inc. has announced the first dosing of a patient in its Phase 1 clinical trial of ONC-783, a new cancer immunotherapy targeting advanced solid tumors.

As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.

OncoC4 is excited to announce that its investigational antibody, Cesalatamig, has received FDA Fast Track designation for treating advanced lung cancer, highlighting progress in cancer therapy.

Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States (NCT06635785) and in China (CTR20253261) Fast Track Designation Supports Expedited Development of Cesalatamig for Non-small Cell Lung Cancer (NSCLC) that Progressed after Concurrent or Sequential PD-(L)1-targeted Immunotherapy and Platinum-based Chemotherapy ROCKVILLE, Md., Sept. 16, 2026 /PRNewswire/ — OncoC4 Inc., a late clinical-stage biopharmaceutical company […]

BioNTech and OncoC4 said median survival reached 18.5 months with gotistobart versus 10 months with docetaxel in a non-pivotal trial stage.

Reported Monday, Sep 14 - 5:09am EDT (TheFly subscription required to read more.)

Updated PRESERVE-003 data: gotistobart showed 18.5 vs 10 months median survival vs chemo in previously treated squamous NSCLC. Pivotal stage ongoing.

OncoC4, a biopharmaceutical leader in cancer and neurodegenerative disease treatment, appoints Dr. Steve Chen as General Counsel to guide legal strategies.

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades...

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ — OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of legal, intellectual property, corporate, and strategic experience across biotechnology, global pharmaceutical companies, private practice, […]

OncoC4, the Rockville, Maryland-based late clinical-stage biopharmaceutical company, has dosed the first patient in a Phase 1 trial of ONC-783, a T-cell…

— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 /PRNewswire/ -- OncoC4 Inc., a...

OncoC4 presents data indicating immunotherapy has potential to become a ‘new class’ of Alzheimer’s drug...

The Maryland biotech that discovered the CD24-Siglec-10 checkpoint and is rewriting the rules of cancer immunotherapy.

BioNTech and OncoC4 shared positive survival data from a late-stage trial of their drug candidate in lung cancer that was previously hit with a partial hold by the FDA.

The cancer immunologist turned serial biotech founder behind OncoC4.

Reported Sunday, Dec 7 - 1:13pm EST (TheFly subscription required to read more.)

OncoC4 Inc. has started dosing the first participant in its Phase 1/2 trial of ONC-841, an innovative Alzheimer’s treatment, after regulatory approval.

OncoC4 announces that China's NMPA has granted Breakthrough Therapy Designation for Gotistobart (BNT316/ONC-392) aimed at treating squamous non-small cell lung cancer, enhancing prospects for patients facing limited options.

OncoC4 has successfully closed a Series B funding round, raising nearly $50 million to further the development of innovative cancer therapies, marking a significant milestone for the company.